8-K/A: AI Tech Group Extends Merger Closing, Adjusts Funding

AI Technology Group Inc. amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp., extending the closing date to July 26, 2026, and revising investment tranches.

Summary

• AI Technology Group Inc. (the Corporation) filed an amendment to its Current Report on Form 8-K to correct the state of incorporation for AVM Biotechnology Inc. from Nevada to Washington.
• The Corporation, AVM Biotechnology Inc., and Biomed 360 Solutions Corp. amended their Agreement and Plan of Merger, originally dated July 31, 2025.
• The closing date for the merger has been extended from March 31, 2026, to July 26, 2026, due to longer merger timelines stemming from financial audit obligations.
• Investment obligations under the merger agreement have been updated with revised dates and amounts for Tranches 1, 2, and 3.
• Tranche 1, a $1,000,000 loan provided by August 1, 2025, by BioMed360, is confirmed and convertible into Parent Shares at $1.00 per share.
• Tranche 2 includes a confirmed $1,000,000 loan provided by November 20, 2025, by AVM Biotechnology Ltd. (Merger Sub), convertible at $2.50 per share.
• Further $1,000,000 Tranche 2 investment increments are scheduled for on or before February 28, 2026, April 30, 2026, and June 30, 2026, also convertible at $2.50 per share.
• Tranche 3 requires a minimum of $10,000,000 and a maximum of $25,000,000 on or before the extended Closing Date, convertible at $2.50 per share.
• Tranche 2 and 3 convertible loan amounts will accrue 10% per annum simple interest, settled in shares at $2.50 per share at the Effective Time.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development. While the amendment clarifies investment tranches, the significant delay in the merger closing, explicitly due to financial audit obligations, introduces uncertainty and suggests potential underlying complexities.

Positives

• Confirmation that Tranche 1 ($1,000,000) and part of Tranche 2 ($1,000,000) loans have already been provided, indicating initial financial commitment to the merger.
• The inclusion of 10% per annum simple interest on Tranche 2 and 3 convertible loans provides a return for the lenders.

Negatives

• The merger closing date has been delayed by nearly four months, from March 31, 2026, to July 26, 2026.
• The delay is attributed to 'longer merger timelines stemming from Financial Audit obligations,' which could indicate complexities or issues in the audit process.

Risks

• The extended merger timeline due to financial audit obligations suggests potential complexities or unforeseen challenges in the audit process, which could further delay or jeopardize the merger.
• Failure to meet the revised investment obligations on their specified dates (subject to a 30-day grace period) would constitute a material breach of the agreement.
• The convertible nature of Tranche 1, 2, and 3 loans at specified rates ($1.00 and $2.50 per share) introduces potential future dilution for existing shareholders.

Future Outlook

The future outlook indicates a prolonged merger process, with the closing now anticipated by July 26, 2026. The company expects to receive additional investment tranches totaling up to $25,000,000 in convertible loans before the new closing date, subject to a 10% annual interest rate.

Management Comments

• Marcus Johnson, Chief Executive Officer of AI Technology Group Inc., signed the First Amendment, indicating the company's agreement to the revised merger terms.
• William Thomas, Chief Executive Officer of Biomed 360 Solutions Corp., signed the First Amendment, signifying their acceptance of the updated agreement.
• Theresa Deisher, Chief Executive Officer and Director of AVM Biotechnology Inc., signed the First Amendment, confirming their consent to the amended terms.

Industry Context

StockSavvy.ai notes that delays in merger agreements, particularly those attributed to 'Financial Audit obligations,' are not uncommon in complex transactions, especially within the biotechnology and technology sectors. Such delays can arise from the intricate due diligence required for integrating diverse financial systems and regulatory compliance, or from uncovering unexpected issues during the audit process. While not necessarily a red flag for deal failure, it often signals increased scrutiny or unforeseen complexities that can extend the integration timeline and potentially impact investor sentiment.

Related Party Transactions

• Tranche 1 loans were provided by BioMed360 on behalf of Parent (AI Technology Group Inc.).
• Part of Tranche 2 loans was provided by AVM Biotechnology Ltd., the Nevada company (Merger Sub), on behalf of Parent (AI Technology Group Inc.).
• The balance of Tranche 2 payments are to be provided by Merger Sub on behalf of Parent or by the Parent directly.

Stakeholder Impact

• Shareholders of AI Technology Group Inc. face extended uncertainty regarding the completion of the merger and potential future dilution from the convertible loans.
• The delay due to financial audit obligations may raise questions among investors about the financial health or reporting practices of the entities involved.
• The revised investment schedule provides clarity for the parties involved in funding the merger, but also extends the period over which these obligations must be met.

Next Steps

• Further $1,000,000 Tranche 2 investment increments are expected on or before February 28, 2026, April 30, 2026, and June 30, 2026.
• The parties will work towards completing the financial audit obligations that are causing the extended merger timeline.
• The merger is expected to close on or before July 26, 2026, with Tranche 3 investments (minimum $10M, maximum $25M) to be provided by this date.

Key Dates

Recommendation

The significant delay in the merger closing, explicitly attributed to financial audit obligations, introduces a notable level of uncertainty and potential risk. While the revised investment tranches provide some clarity on funding, the extended timeline suggests complexities that warrant a cautious 'hold' stance. Investors should monitor further developments regarding the audit and the progression towards the new closing date before making definitive investment decisions.

Keywords

Merger Agreement, SEC Filing, 8-K/A, AI Technology Group, AVM Biotechnology, Biomed 360 Solutions, Merger Delay, Investment Tranches, Convertible Loans, Financial Audit, Corporate Action